Handelsbanken Fonder
RUBY

Handelsbanken Fonder’s Rubius Therapeutics, Inc RUBY Stock Holding History

Handelsbanken Fonder’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-14,900
Closed -$82K – 1716
2022
Q1 		$82K Hold
14,900
– – ﹤0.01% 1689
2021
Q4 		$144K Buy
14,900
+2,700
+22% +$37.4K ﹤0.01% 1731
2021
Q3 		$218K Hold
12,200
– – ﹤0.01% 1645
2021
Q2 		$298K Buy
+12,200
New +$305K ﹤0.01% 1630

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AFM
Abbot Financial Management Andover, Massachusetts $293M AUM 36.12% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Handelsbanken Fonder's RUBY Position: Q2 2022 in Review

Handelsbanken Fonder sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2022, closing a stake of 14,900 shares — an estimated $82K sold.

Handelsbanken Fonder first reported a position in RUBY in Q2 2021 and held it in 4 quarters. The position peaked at $298K in Q2 2021. 72 funds tracked by Wall St. Rank hold RUBY as of Q2 2022.

  • Handelsbanken Fonder reported no remaining Rubius Therapeutics, Inc position as of Q2 2022 after selling out during the quarter.
  • Handelsbanken Fonder sold 14,900 Rubius Therapeutics, Inc shares in Q2 2022, an estimated $82K.
  • Handelsbanken Fonder first reported a position in Rubius Therapeutics, Inc in Q2 2021 and held it in 4 quarters.
  • Handelsbanken Fonder's Rubius Therapeutics, Inc position peaked at $298K in Q2 2021.
  • 72 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2022.

Based on Handelsbanken Fonder's 13F filing for Q2 2022, filed 3 Aug 2022.